IONIS PHARMACEUTICALS INC
CIK 874015 · last filed 2020-10-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
2
Total Filings
13
Lifetime Open-Market Net
$222.50M
Filer Profile
Reported Address
2855 GAZELLE COURTCARLSBAD, CA 92010
Phone
(760) 931-9200
State of Incorporation
CA
Formerly Known As
ISIS PHARMACEUTICALS INC (1996–2015)
Related Filers
C FRANK BENNETT — 157 joint filings, latest 2026-07-09
B LYNNE PARSHALL — 155 joint filings, latest 2026-04-17
STANLEY T CROOKE — 137 joint filings, latest 2021-01-28
PATRICK R. O'NEIL — 137 joint filings, latest 2026-06-30
Brett P Monia — 130 joint filings, latest 2026-06-26
Richard S Geary — 115 joint filings, latest 2025-11-07
JOSEPH KLEIN III — 84 joint filings, latest 2026-07-06
ELIZABETH L HOUGEN — 82 joint filings, latest 2026-03-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | 10%+ Owner | 77,094,682 | — | — | $225.00M | 6 | 2019-12-19 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 45,426 | $8.16 | $370.7K | -$2.50M | 6 | 2015-07-17 |
Recent Filings · Page 2 of 2
13 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-07-25 | Regulus Therapeutics Inc. (RGLS) Delisted | Sell (S) | −10,500 | -$70.9K | EDGAR |
| 2014-07-07 | Regulus Therapeutics Inc. (RGLS) Delisted | Sell (S) | −8,600 | -$69.4K | EDGAR |
| 2012-10-11 | Regulus Therapeutics Inc. (RGLS) Delisted | Mixed | +7,049,500 | $3.00M | EDGAR |
Showing 11–13 of 13
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.